Randomized-controlled Trial of the Effectiveness of COVID-19 Early Treatment in Community
Status:
Recruiting
Trial end date:
2022-01-30
Target enrollment:
Participant gender:
Summary
There is an urgent need to identify effective treatments for SARS-CoV-2 infection that helps
people recover quicker and reduces the need for hospital admission. The investigators develop
an open, adaptive, platform trial to evaluate treatments, Fluvoxamine, Bromhexine,
Cyproheptadine, and Niclosamide suitable for use in the community for treating
COVID-like-illness that might help people recover sooner and prevent hospitalisation.
Phase:
Phase 4
Details
Lead Sponsor:
Chulalongkorn University
Collaborators:
King Chulalongkorn Memorial Hospital Mae Fah Luang University Mahidol University Ministry of Health, Thailand QIMR Berghofer Medical Research Institute Rajavithi Hospital Ramathibodi Hospital The University of Western Australia Washington University School of Medicine Yamagata Prefectural Central Hospital